Publication | Closed Access

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial

OncologySingle ArmMedicinePathologyT790m MutationAnti-cancer AgentCancer TreatmentAnti-tumor ActivityPharmacologyRadiation OncologyLung Cancer